APA (7th ed.) Citation

Federico Diotallevi, Giulia Matacchione, Giovanni Marco d'Agostino, Helena Gioacchini, Anna Campanati, Jacopo Sabbatinelli, . . . Annamaria Offidani. (2023). InflammamiR-146a and -155 Plasma Levels are Associated with Clinical Efficacy of Risankizumab Treatment in Psoriatic Patients: Pilot Study. Adis, Springer Healthcare.

Chicago Style (17th ed.) Citation

Federico Diotallevi, Giulia Matacchione, Giovanni Marco d'Agostino, Helena Gioacchini, Anna Campanati, Jacopo Sabbatinelli, Fabiola Olivieri, and Annamaria Offidani. InflammamiR-146a and -155 Plasma Levels Are Associated with Clinical Efficacy of Risankizumab Treatment in Psoriatic Patients: Pilot Study. Adis, Springer Healthcare, 2023.

MLA (9th ed.) Citation

Federico Diotallevi, et al. InflammamiR-146a and -155 Plasma Levels Are Associated with Clinical Efficacy of Risankizumab Treatment in Psoriatic Patients: Pilot Study. Adis, Springer Healthcare, 2023.